Unconventional Cancer Treatments
Appendix B: Glossary of Abbreviations
- AAM: Alliance for Alternative Medicine
- ACCC: Association of Community Cancer Centers
- ACS: American Cancer Society
- ACSH: American Council on Science and Health
- ADS: Agua del Sol
- AIDS: Acquired Immune Deficiency Syndrome
- AMA: American Medical Association
- AQA: American Quack Association
- ASCO: American Society for Clinical Oncology
- BC/BS: Blue Cross/Blue Shield
- BCBSA: Blue Cross and Blue Shield Association
- BCBSNJ: Blue Cross/Blue Shield of New Jersey
- BCG: bacillus Calmette-Guerin
- BP: Blocking Protein
- BPF: Blocking Protein Factor
- CACR: Center for Alternative Cancer Research
- CAG: Clinical Appraisal Group
- Caltech: California Institute of Technology
- CANAH: Coalition for Alternatives in Nutrition and Healthcare
- CCS: Cancer Control Society
- CDC: Centers for Disease Control (Public Health Service, DHHS)
- CFCM: Committee for Freedom of Choice in Medicine
- CHAMPUS: Civilian Health and Medical Program of the Uniformed Services
- CIS: Cancer Information Service (NCI)
- CPT: Current Procedural Terminology (4th edition)
- CRS: Cancer Response System (ACS)
- CT: computed tomography
- DATTA: Diagnostic and Therapeutic Technology Assessment program (AMA)
- DHHS: U.S. Department of Health and Human Services
- DMF: Drug Master File
- DMSO: dimethyl sulfoxide
- DNA: deoxyribonucleic acid
- DNCP: Diet, Nutrition, and Cancer Program (NCI)
- DO: doctor of osteopathy
- DP: Deblocking Protein
- DPF: Deblocking Protein Factor
- ECaP: Exceptional Cancer Patients
- ELISA: enzyme-linked immunosorbent assay
- ERISA: Employee Retirement Income Security Act
- FACT: Foundation for Advancement in Cancer Therapies
- FAM: Foundation for Alternative Medicine
- FDA: Food and Drug Administration (DHHS)
- FDCA: Federal Food, Drug, and Cosmetic Act
- FTC: Federal Trade Commission
- FTCA: Federal Trade Commission Act
- GAO: General Accounting Office (U.S. Congress)
- GRAS: generally recognized as safe
- HCFA: Health Care Financing Administration (DHHS)
- HCG: human chorionic gonadotropin
- HIV: human immunodeficiency virus
- HNF: Hans Nieper Foundation
- HPB: Health Protection Branch, Health and Welfare Canada
- HTLV-III: human T-cell lymphotropic virus, type III (formerly, human T-cell leukemia virus, type III) (see HIV)
- IACVF: International Association of Cancer Victors and Friends
- IAT: Immuno-Augmentative Therapy
- IATPA: IAT Patients' Association
- ICD: International Classification of Diseases (9th revision)
- IL-2: interleukin-2
- IND: Investigational New Drug
- IRB: Institutional Review Board
- IRC: Immunology Researching Centre, Inc. (Bahamas)
- IRF: Immunology Research Foundation (Great Neck, NY)
- JCAHO: Joint Commission on Accreditation of Health Care Organizations
- LAV: lymphadenopathy-associated virus
- MAC: Multispecialty Advisory Committee (BCBSNJ)
- MCHSF: Medicare Continuous History Sample File
- MD: medical doctor
- MNP: Medical Necessity Program (BCBSA)
- MSKCC: Memorial Sloan-Kettering Cancer Center
- NACAA: National Association of Consumer Agency Administrators
- NAPRALERT: Natural Product Data Base
- NCAHF: National Council Against Health Fraud
- NCI: National Cancer Institute (NIH)
- NDA: new drug application
- NDGA: nordihydroguaiarectic acid
- NHCAA: National Health Care Anti-Fraud Association
- NHF: National Health Federation
- NHL: non-Hodgkins lymphoma
- NIH: National Institutes of Health (DHHS)
- NK: natural killer (cells)
- NRC: National Research Council (National Academy of Sciences)
- OPMC: Office of Professional Medical Conduct (State of New York)
- OTA: Office of Technology Assessment (U.S. Congress)
- PAC: Pharmaceutical Advertising Council
- PAHO: Pan American Health Organization
- PC: Progenitor cryptocides
- PDQ: Physician Data Query (NCI)
- PDT: photodynamic therapy
- PNI: psychoneuroimmunology
- PRO: utilization and quality control peer review organization
- RCT: randomized clinical trial
- RDA: recommended daily allowance
- RICO: Racketeer Influenced and Corrupt Organizations Act
- SEER: Surveillance, Epidemiology, and End Results Program (NCI)
- TA1: Tumor Antibody 1
- TA2: Tumor Antibody 2
- TC: Tumour Complement
- TEC: Technology Evaluation and Coverage Program (BCBSA)
- TIF: tumor induction factor
- TNF: tumor necrosis factor
- UCLA: University of California at Los Angeles
- USCA: U.S. Court of Appeals
- USP: U.S. Pharmacopeia
- USP DI: U.S. Pharmacopeial Dispensing Information
- USPS: U.S. Postal Service
- ACCC: Association of Community Cancer Centers
OTA Report Contents ||| OTA Report Index
This page was posted on August 3, 1998.